An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Summary

This study consisted of 2 parts: a double-blind (DB) phase and an open-label extension (OLE) phase. Only the OLE phase is described in this record. The OLE phase was a safety study. All participants received GWP42003-P initially titrated to 20 milligrams (mg)/kilograms (kg)/day; however, investigators subsequently decreased or increased the participant's dose to a maximum of 30 mg/kg/day (no minimum).

Timeline

Start

2016-03-11

Primary completion

2017-06-07

Completion

2017-06-07

Drugs

Indications